CA2113683A1 - Traitement des maladies proliferatives, metastases et tumeurs pharmacoresistantes par des composes vanadate et derives ou analogues de vanadate - Google Patents

Traitement des maladies proliferatives, metastases et tumeurs pharmacoresistantes par des composes vanadate et derives ou analogues de vanadate

Info

Publication number
CA2113683A1
CA2113683A1 CA002113683A CA2113683A CA2113683A1 CA 2113683 A1 CA2113683 A1 CA 2113683A1 CA 002113683 A CA002113683 A CA 002113683A CA 2113683 A CA2113683 A CA 2113683A CA 2113683 A1 CA2113683 A1 CA 2113683A1
Authority
CA
Canada
Prior art keywords
orthovanadate
vanadate
cells
drug resistant
vanadate compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002113683A
Other languages
English (en)
Inventor
Tony Cruz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mount Sinai Hospital Corp
Original Assignee
Mount Sinai Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mount Sinai Hospital Corp filed Critical Mount Sinai Hospital Corp
Priority to CA002113683A priority Critical patent/CA2113683A1/fr
Publication of CA2113683A1 publication Critical patent/CA2113683A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
CA002113683A 1994-01-18 1994-01-18 Traitement des maladies proliferatives, metastases et tumeurs pharmacoresistantes par des composes vanadate et derives ou analogues de vanadate Abandoned CA2113683A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002113683A CA2113683A1 (fr) 1994-01-18 1994-01-18 Traitement des maladies proliferatives, metastases et tumeurs pharmacoresistantes par des composes vanadate et derives ou analogues de vanadate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002113683A CA2113683A1 (fr) 1994-01-18 1994-01-18 Traitement des maladies proliferatives, metastases et tumeurs pharmacoresistantes par des composes vanadate et derives ou analogues de vanadate

Publications (1)

Publication Number Publication Date
CA2113683A1 true CA2113683A1 (fr) 1995-07-19

Family

ID=4152759

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002113683A Abandoned CA2113683A1 (fr) 1994-01-18 1994-01-18 Traitement des maladies proliferatives, metastases et tumeurs pharmacoresistantes par des composes vanadate et derives ou analogues de vanadate

Country Status (1)

Country Link
CA (1) CA2113683A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996011004A1 (fr) * 1994-10-05 1996-04-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Agent pour le traitement de lesions malignes et pre-malignes positives de papillomavirus
WO1997045105A1 (fr) * 1996-05-24 1997-12-04 Angiotech Pharmaceuticals, Inc. Compositions et methodes pour traiter ou prevenir des maladies des voies corporelles
WO1997047296A2 (fr) * 1996-06-12 1997-12-18 Mount Sinai Hospital Corporation Compositions contenant des composes de vanadium utilisees dans le traitement des maladies proliferatives et des arthropathies

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996011004A1 (fr) * 1994-10-05 1996-04-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Agent pour le traitement de lesions malignes et pre-malignes positives de papillomavirus
US6238659B1 (en) 1994-10-05 2001-05-29 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Agent for treating papilloma virus-positive malignant and premalignant lesions
WO1997045105A1 (fr) * 1996-05-24 1997-12-04 Angiotech Pharmaceuticals, Inc. Compositions et methodes pour traiter ou prevenir des maladies des voies corporelles
US6759431B2 (en) 1996-05-24 2004-07-06 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing diseases of body passageways
JP2004285074A (ja) * 1996-05-24 2004-10-14 Angiotech Pharmaceuticals Inc 身体通路の疾患を処置または予防するための組成物および方法
WO1997047296A2 (fr) * 1996-06-12 1997-12-18 Mount Sinai Hospital Corporation Compositions contenant des composes de vanadium utilisees dans le traitement des maladies proliferatives et des arthropathies
WO1997047296A3 (fr) * 1996-06-12 1998-03-05 Mount Sinai Hospital Corp Compositions contenant des composes de vanadium utilisees dans le traitement des maladies proliferatives et des arthropathies

Similar Documents

Publication Publication Date Title
US5871779A (en) Treatment of arthropathies with vanadate compounds or analogues thereof
Witschi et al. Modulation of lung tumor development in mice with the soybean-derived Bowman—Birk protease inhibitor
Zuckerbraun et al. Carbon monoxide signals via inhibition of cytochrome c oxidase and generation of mitochondrial reactive oxygen species
Jiao et al. Studies on anti-tumor and antimetastatic activities of fullerenol in a mouse breast cancer model
Stearns et al. Taxol blocks processes essential for prostate tumor cell (PC-3 ML) invasion and metastases
Blask et al. Physiological melatonin inhibition of human breast cancer cell growth in vitro: evidence for a glutathione-mediated pathway
US5843481A (en) Treatment of proliferative disorders, metastasaes, and drug resistant tumors with vanadate compounds and derivatives or analogues thereof
Brandt et al. Augmentation of intracellular iron using iron sucrose enhances the toxicity of pharmacological ascorbate in colon cancer cells
Satoh et al. Modulation of both cisplatin nephrotoxicity and drug resistance in murine bladder tumor by controlling metallothionein synthesis
US20010053356A1 (en) Garlic ingredients and antioxidants in the prevention and treatment of vascular-related disorders and pathological angiogenesis-mediated disorders
Shahjahan et al. Effect of Solanum trilobatum on the antioxidant status during diethyl nitrosamine induced and phenobarbital promoted hepatocarcinogenesis in rat
Bose et al. Critical role of allyl groups and disulfide chain in induction of Pi class glutathione transferase in mouse tissues in vivo by diallyl disulfide, a naturally occurring chemopreventive agent in garlic
Pierson et al. Sodium ascorbate enhancement of carbidopa-levodopa methyl ester antitumor activity against pigmented B16 melanoma
Kar et al. The dual role of boron in vitro neurotoxication of glioblastoma cells via SEMA3F/NRP2 and ferroptosis signaling pathways
Salim Removing oxygen-derived free radicals delays hepatic metastases and prolongs survival in colonic cancer: A study in the rat
US20040167217A1 (en) Neuroprotective effects of polyphenolic compounds
Kish et al. Magnetic resonance imaging of ethyl-nitrosourea-induced rat gliomas: a model for experimental therapeutics of low-grade gliomas
Sadzuka et al. Caffeine modulates the antitumor activity and toxic side effects of adriamycin
US20220249438A1 (en) Carbocyanine compounds for targeting mitochondria and eradicating cancer stem cells
CA2113683A1 (fr) Traitement des maladies proliferatives, metastases et tumeurs pharmacoresistantes par des composes vanadate et derives ou analogues de vanadate
Selman et al. A comparative study of the inhibiting effects of mitomycin C and polyphenolic catechins on tumor cell implantation/growth in a rat bladder tumor model
DEULOFEU et al. S-adenosylmethionine prevents hepatic tocopherol depletion in carbon tetrachloride-injured rats
Simpson et al. β-Aminopropionitrile-induced aortic ruptures in turkeys: Inhibition by reserpine and enhancement by monoamine oxidase inhibitors
US20030012825A1 (en) Metallized molecule therapies
MXPA96002846A (en) Vanadato compounds for the treatment of proliferative disorders, metastases, and farm-resistant tumors

Legal Events

Date Code Title Description
FZDE Discontinued